NCNaeem Chaudhri

Naeem Chaudhri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Naeem Chaudhri has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Mahmoud Aljurf

    King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

    4 shared publications
  • Fahad Alsharif

    Adult Hematology/HSCT Section, Oncology Center, King Faisal Specialist Hospital and Research Centre, (KFSH&RC), Riyadh, 11211 Saudi Arabia

    3 shared publications
  • Syed Osman Ahmed

    Adult Hematology/HSCT Section, Oncology Center, King Faisal Specialist Hospital and Research Centre, (KFSH&RC), Riyadh, 11211 Saudi Arabia

    3 shared publications
  • Mahmoud Aljurf

    Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

    2 shared publications
  • Said Yousuf Mohamed

    King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia

    2 shared publications
  • Tarek Owaidah

    Hematopathology Section, Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, (KFSH&RC), Riyadh, 11211 Saudi Arabia

    2 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors

    by Dietger Niederwieser, Helen Baldomero, Nosa Bazuaye, Caitrin Bupp, Naeem Chaudhri, Selim Corbacioglu, Alaa Elhaddad, Cristóbal Frutos, Sebastian Galeano, Nada Hamad, et al.

    The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission of promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries and individual centers. In 2016, 82,718 first HCT were reported by 1,662 HCT teams in 86 of the 195 World Health Organization member states representing a global increase of 6.2% in autologous HCT and 7.0% in allogeneic HCT and bringing the total to 1,298,897 procedures. Assuming a frequency of 84,000/year, 1.5 million HCT were performed by 2019 since 1957. Slightly more autologous (53.5%) than allogeneic and more related (53.6%) than unrelated HCT were reported. A remarkable increase was noted in haploidentical related HCT for leukemias and lymphoproliferative diseases, but even more in non-malignant diseases. Transplant rates (TR; HCT/10 million population) varied according to region reaching 560.8 in North America, 438.5 in Europe, 76.7 in Latin America, 53.6 in South East Asia/Western Pacific (SEA/WPR) and 27.8 in African/East Mediterranean (AFR/EMR). Interestingly, haploidentical TR amounted to 32% in SEA/WPR and 26% in Latin America, but only 14% in Europe and EMR and 4.9% in North America of all allogeneic HCT. HCT team density (teams/10 million population) was highest in Europe (7.7) followed by North America (6.0), SEA/WPR (1.9), Latin America (1.6) and AFR/EMR (0.4). HCT are increasing steadily worldwide with narrowing gaps between regions and greater increase in allogeneic compared to autologous activity. While related HCT is rising, largely due to increase in haploidentical HCT, unrelated HCT is plateauing and cord blood HCT is in decline.


  • Open Access

    Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies

    by Naeem A. Chaudhri, Mahmoud Aljurf, Fahad I. Almohareb, Hazzaa A. Alzahrani, Qaiser Bashir, Bipin Savani, Vikas Gupta, Shahrukh K. Hashmi

    More than 70,000 hematopoietic cell transplants are currently performed each year, and these continue to increase every year. However, there is a significant variation in the number of absolute transplants and transplant rates between centers, countries, and global regions. The prospect for emerging countries to develop a hematopoietic cell transplantation (HCT) program, as well as to decide on whether autologous HCT (auto-HCT) or allogeneic HCT (allo-HCT) should be established to start with, relies heavily on factors that can explain differences between these two procedures. Major factors that will influence a decision about establishing the type of HCT program are macroeconomic factors such as organization of the healthcare network, available resources and infrastructure. Prevalence of specific diseases in the region as well genetic background of donors and recipients will also influence the mandate or priority of the HCT in the national healthcare plan to explain some of the country-specific differences. Furthermore, microeconomic factors play a role, such as center-specific experience in treating various disorders requiring hematopoietic stem cell transplantation, along with accreditation status and patient volume. The objective of the transplant procedure was to improve the survival anc quality of life of patients. The regional difference that one notices in emerging countries about the higher number of allo-HCT compared with auto-HCT procedures performed is primarily based on suboptimal healthcare network in treating various malignant disorders that are the primary indication for auto-stem cell transplantation. In this context, nonmalignant disorders such as bone marrow failure syndromes, inherited genetic disorders and hemoglobinopathies have become the major indication for stem cell transplantation. Better understanding of these factors will assist in establishing new transplant centers in the emerging countries to achieve their specific objectives and positive outcome.


  • Open Access

    Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia

    by Haneen Banjar, Damith Ranasinghe, Fred Brown, David Adelson, Trent Kroger, Tamara Leclercq, Deborah White, Timothy Hughes, Naeem Chaudhri

    Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly difficult in recent years due to the variety of treatment options available and challenge deciding on the most appropriate treatment strategy for an individual patient. To facilitate the treatment strategy decision, disease assessment should involve molecular response to initial treatment for an individual patient. Patients predicted not to achieve major molecular response (MMR) at 24 months to frontline imatinib may be better treated with alternative frontline therapies, such as nilotinib or dasatinib. The aims of this study were to i) understand the clinical prediction ‘rules’ for predicting MMR at 24 months for CML patients treated with imatinib using clinical, molecular, and cell count observations (predictive factors collected at diagnosis and categorised based on available knowledge) and ii) develop a predictive model for CML treatment management. This predictive model was developed, based on CML patients undergoing imatinib therapy enrolled in the TIDEL II clinical trial with an experimentally identified achieving MMR group and non-achieving MMR group, by addressing the challenge as a machine learning problem. The recommended model was validated externally using an independent data set from King Faisal Specialist Hospital and Research Centre, Saudi Arabia. The common prognostic scores yielded similar sensitivity performance in testing and validation datasets and are therefore good predictors of the positive group. The G-mean and F-score values in our models outperformed the common prognostic scores in testing and validation datasets and are therefore good predictors for both the positive and negative groups. Furthermore, a high PPV above 65% indicated that our models are appropriate for making decisions at diagnosis and pre-therapy. Study limitations include that prior knowledge may change based on varying expert opinions; hence, representing the category boundaries of each predictive factor could dramatically change performance of the models.


  • Open Access

    Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patients

    by Ayodele A. Alaiya, Mahmoud Aljurf, Zakia Shinwari, Fahad Almohareb, Hafiz Malhan, Hazzaa Alzahrani, Tarek Owaidah, Jonathan Fox, Fahad Alsharif, Said Y. Mohamed, et al.

    There is unmet need for prediction of treatment response for chronic myeloid leukemia (CML) patients. The present study aims to identify disease-specific/disease-associated protein biomarkers detectable in bone marrow and peripheral blood for objective prediction of individual's best treatment options and prognostic monitoring of CML patients. Bone marrow plasma (BMP) and peripheral blood plasma (PBP) samples from newly-diagnosed chronic-phase CML patients were subjected to expression-proteomics using quantitative two-dimensional gel electrophoresis (2-DE) and label-free liquid chromatography tandem mass spectrometry (LC-MS/MS). Analysis of 2-DE protein fingerprints preceding therapy commencement accurately predicts 13 individuals that achieved major molecular response (MMR) at 6 months from 12 subjects without MMR (No-MMR). Results were independently validated using LC-MS/MS analysis of BMP and PBP from patients that have more than 24 months followed-up. One hundred and sixty-four and 138 proteins with significant differential expression profiles were identified from PBP and BMP, respectively and only 54 proteins overlap between the two datasets. The protein panels also discriminates accurately patients that stay on imatinib treatment from patients ultimately needing alternative treatment. Among the identified proteins are TYRO3, a member of TAM family of receptor tyrosine kinases (RTKs), the S100A8, and MYC and all of which have been implicated in CML. Our findings indicate analyses of a panel of protein signatures is capable of objective prediction of molecular response and therapy choice for CML patients at diagnosis as ‘personalized-medicine-model’.


  • Efficacy and safety of VCEP-M for induction treatment of mixed phenotypic acute leukemia.

    by Ahmad Alhuraiji, Ahmad Shad, Tarek Owaidah, Hazza Alzahrani, Fahed Al Mhareb, Naeem Chaudhri, Fahad Alsharif, Said Mohamed, Ghuzayel Al Dawsari, Mohammad Islam, et al.

    E18504 Background: Mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia, characterized by an aggressive behavior and a tendency towards resistance to therapy and overall poor outcome. The aim of the study is to evaluate the efficacy and toxicity of VCEP-M protocol. Methods: A retrospective study. We included patients diagnosed with mixed phenotypic acute leukemia at King Faisal Specialist Hospital and research Centre (based on WHO and EGIL criteria) from 2002-2014 treated with upfront VCEP-M Protocol. We excluded patients who are less than 15 years of age and patients treated outside our institution. Data were collected from our electronic tumor registry. Results: We included 19 patients who met the inclusion criteria. Baseline characterisitics are shown below. Ten patients were salvaged at Day 14 Bone marrow with Fludarabine 30mg/m2/d and cytarabine 2gm/m2/d (D1-5) (FA) chemotherapy. Complete remission (CR) rate at day 28 bone marrow was 95% (18 patients). Thirteen patients proceeded to allogenic stem cell transplantation (SCT). All 6 patients who had not had SCT died. Overall survival (OS) and disease free survival (DFS) at 5 years were 54% and 57% respectively. Treatment related toxicity were mainly sepsis (11 patients) and disseminated intravascular coagulation (DIC) (2 patients). There was no reported treatment related deaths. Conclusions: VCEP-M appears effective in the treatment of MPAL with a safe toxicity profile. All patients would likely benefit from SCT.


  • Open Access

    Leukemia during pregnancy

    by Ajm Saleh, Ayman Alhejazi, Syed Osman Ahmed, Fahad Al Mohareb, Fahad AlSharif, Hazza AlZahrani, Said Yousuf Mohamed, Walid Rasheed, Ghuzayel AlDawsari, Khalid Ibrahim, et al.

    BACKGROUND AND OBJECTIVES: There is limited information regarding the outcome of patients treated for leukemia during pregnancy. This study was performed on all cases of leukemia during pregnancy identified in our institution leukemia database. PATIENTS AND METHODS: It is a retrospective study from our existing database. Thirty two cases were identified among the cohort of patients treated for acute and chronic leukemia between January 1991 and July 2003. RESULTS: Among the acute leukemia patients (n = 21), 10 patients (47.6%) received chemotherapy during pregnancy, seven had live birth and three had spontaneous abortion. No teratogenicity or congenital malformations or postnatal complication were reported. The remaining 11 (52.4%) were not given chemotherapy while pregnant; three patients presented after 34 weeks of gestation ending in normal live births and then received chemotherapy and eight patients had abortion before starting chemotherapy.Among the chronic myeloid leukemia (CML) patients (n = 11), nine patients received hydroxyurea, one patient received alfa-interferon and one patient was treated with leukapheresis. Eight patients had normal live births and three patients had abortion. Out of the 32 patients, 18 patients (56.2%) subsequently underwent HLA matched sibling allogeneic stem cell transplantation, seven for acute myeloid leukemia (AML), two for acute lymphocytic leukemia (ALL) and nine for CML. After a median follow up of 16 years, five patients (15.6%) are alive in remission (one fromchemotherapy group and four from SCT group). CONCLUSIONS: Our report lends credence to the safety and feasibility of administering anti-leukemic therapy in acute and chronic leukemias during pregnancy although acute leukemia patients had possibly a poor long term outcome compared to non-pregnant patients.


    • 1 December 2011
      • Vol. 9  (6) , 432-3

    Leukemia relapse after allogeneic bone marrow transplantation: how does chronic graft-versus-host disease influence the pattern and onset of relapse?

    by A Al Beihany, F Al Mohareb, H Al Zahrani, Fahad Alsharif, Naeem Chaudhri, Said Yousuf Mohamed, Walid Rasheed, Mahmoud Aljurf

    We describe a pattern of relapse in 601 patients who received an allogeneic hematopoietic stem cell transplant at our institution for acute or chronic leukemia and myelodysplasia over a period of 18 years. We show a correlation between chronic graft-versus-host disease and extramedullary relapse, suggesting that the expected graft versus leukemia effect in patients with chronic graft-versus-host disease may preferentially maintain marrow remission without preventing relapse in extramedullary sites.


  • Open Access

    Klebsiella oxytoca bacteremia causing septic shock in recipients of hematopoietic stem cell transplant: Two case reports

    by Khalid A Al-Anazi, Asma M Al-Jasser, Hazza A Al-Zahrani, Naem Chaudhri, Fahad I Al-Mohareb

    Klebsiella oxytoca can cause various infectious complications in healthy as well as in immunocompromised individuals. Case 1: A 49 year old female with multiple myeloma received an autologous hematopoietic stem cell transplant in October 2005. Eight days following her autograft she developed septic shock caused by Klebsiella oxytoca bacteremia which was successfully treated with intravenous meropenem and gentamicin. Case 2: A 29 year old female with sickle cell anemia and severe aplastic anemia underwent an allogeneic hematopoietic stem cell transplant in July 2005. Seven months following her unsuccessful allograft, she developed septic shock due to Klebsiella oxytoca bacteremia caused by a urinary tract infection. The septic episode was successfully managed with intravenous meropenem and gentamicin. Both patients were treated at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia. To our knowledge, they are the first reports of Klebsiella oxytoca bacteremias and septic shocks in hematopoietic stem cell transplant recipients. Klebsiella oxytoca should be considered as a possible cause of severe infections in recipients of various forms of hematopoietic stem cell transplantation. However, these infections may be complicated by bacteremias, septic shocks, systemic dysfunctions and even deaths if not managed promptly and appropriately.